Download BIPOLAR DISORDERS

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
“AFTER ALL, THERE IS
NOTHING AS INTERESTING AS
PEOPLE, AND ONE CAN
NEVER STUDY THEM
ENOUGH”
VINCENT VAN GOGH
BIPOLAR DISORDERS
• Closely Kept Secrets
• New Treatments
EPIDEMIOLOGY OF
BIPOLAR DISORDER
• Prevalence is underestimated at 1%
• Prevalence is probably 2%
• Calgary est. 2%x890000=17,800 citizens
COMORBID DISORDERS
• Substance Abuse – At least 61%
• Alcohol, Cocaine, THC
• Effect – More mixed and rapid cycling, poorer
response to Lithium, slower time to recovery, and
more lifetime hospitalizations
• Narcissistic PD
• Borderline PD
• 20-30% OCD, Panic Disorder
DIFFERENTIAL DIAGNOSIS
•
•
•
•
•
•
Schizophrenia, Schizoaffective disorder
Substance Abuse – Stimulants
Pseudo-Unipolar Disorder
Steroids, Ginseng, Valerian root
Syphilis, Hyperparathyroidism
Borderline, Narcissistic and Histrionic
Personality disorder
ADOLESCENCE
• Much more likely to be delusional and co
morbid for substance abuse
• More likely to be irritable and misdiagnosed
as conduct disorder
PRECIPITANTS
• 60% of first episodes precipitated by
psychosocial, physical, or drug causes
30% of second episodes
• None of fourth episodes
• Illness starts as exogenous and becomes
more endogenous
• Concept of kindling
SCREENING QUESTIONS
• Have you ever had a period of a week or so
when you felt so happy and energetic that
your friends told you that you were talking
too fast or that you were behaving
differently and strangely?
• Has there been a period when you were so
hyper and irritable that you got into
arguments with people?
SCREENING QUESTIONS
• Has anyone ever called you manic before?
DIGFAST
•
•
•
•
•
•
•
Distractibility
Indiscretion (pleasurable activities)
Grandiosity
Flight of ideas
Activity increase
Sleep deficit (decreased need)
Talkativeness (pressured speech)
DISTRACTABILITY
• Were you having trouble thinking or
concentrating?
• Was this because things around you or even
your thoughts were getting you off track?
INDISCRETION
• During the period we were talking about, how
were you spending your time?
• Were you doing things that caused trouble for you
or your family?
• Were you doing things that showed a lack of
judgment, such as driving too fast, running red
lights, or spending too much?
• Were you doing sexual things during this
INDISCRETIONS
this period that was unusual for you?
GRANDIOUSITY
• During this period did you feel so confidant
that you felt you could conquer the world?
• What was your best idea when you felt that
way?
• Did you feel that you had special powers or
abilities?
• Did you feel more religious than normal for
you?
FLIGHT OF IDEAS
• During this period did you have so many
thoughts, or were they so fast, that you
could barely keep up to them?
• Did it feel like your thoughts were racing?
ACTIVITY INCREASE
• During that period, were you more active
than usual?
• Were you constantly starting new projects
and hobbies, working into the night?
SLEEP DEFICIT
• During that period, did you need less sleep?
• Did you ever stay up all night doing all
kinds of things, like working on projects or
phoning people?
• Did your sleep duration become reduced
and still you had lots of energy?
TALKATIVENESS
• During this period, were you talking more
than usual for you?
• Were you talking so much that people had
to interrupt you to speak to you?
• Were you using the phone more than usual
for you?
CORROBORATION
• Denial and lack of insight rule the day
TREATMENT OPTIONS
• Hospitalization for mania, severe depression
• Mood stabilizers, antipsychotics and
antidepressants
• ECT – most effective treatment
• Supportive psychotherapy and CBT
• Lifestyle change
• Substance abuse treatment
LITHIUM CARBONATE
• 900 – 1500 mg/d .8-1.3 mEq/L
• Most effective medication
• SE’s include teratogenicity, tremor, renal
dysfunction, acne, hypothyroidism, gastric upset,
cardiac conduction problems, cognitive
impairment
• Serum TSH, Cr, EKG, electrolytes pre and TSH,
Cr q6mo.
• Mogen Schou rule, “Always treat SE’s”
CARBAMAZEPINE
• 400 – 1000 mg/d
• Most effective for mixed states, rapid
cycling
• SE’s – sedation, ataxia, aplastic anemia,
agranulocytosis
• Check CBC q3mo ?
VALPROATE
• 500 – 2000 mg/d; Highest blood level for
effect. Highest dose is 60 mg/kg/d
• SE’s – GI upset, weight gain, alopecia,
teratogenicity, liver problems
• Best for mixed states, rapid cycling,
secondary mania. Ineffective for depression
• Selenium for hair loss
• PCOD!
ATYPICAL ANTIPSYCHOTICS
• Olanzepine – 2.5-20 mg/d; very effective;
significant wt gain and lipid problems in
some
• Risperdal - .5-4.0 mg/d; more EPS and
increased prolactin in some
• Clozapine - For truly refractory patient, but
can be remarkably effective. Slow response,
serious SE profile and significant wt gain
Olanzepine Efficacy for Mania:
Two Placebo-Controlled Studies
•
Both double-blind, placebo-controlled, inpatient
– Study I:
3 weeks*
– Study II:
4 weeks**
•
Olanzapine dosage: 5-20 mg/day
– Starting daily dose:
– Mean modal daily dose:
Study I
Study II
Study I
Study II
•
DSM-IV Bipolar I Disorder, manic or mixed
•
Lorazepam use limited to initial study phase
- 10 mg
- 15 mg
- 14.9 mg
- 16.4 mg
* Study I -Tohen et al, Am J Psych 1999;
** Study II- Tohen et al, XI World Congress of Psychiatry, Hamburg Germany, 1999
Olanzepine Grp. Superior YMRS
Scores
Mean Change to
Endpoint (LOCF)
Baseline
0
:
Study I
three weeks
28.7
27.7
n=70
n=66
Study II
four weeks
28.8
29.4
n=54
n=56
-4.9
-10
-10.3
*
-20
-8.1
-14.8
**
Olanzapine
Placebo
Y-MRS Total score designated a priori as primary outcome measure.
*p=0.02, **p<0.001; LOCF
Antimanic Efficacy of Olanzapine Is
Significant Starting at the First Assessment
(Week 1 Y-MRS)
0
15 mg starting dose
-10
Percent -20
Change
from
-30
Baseline
in Y-MRS -40
Total
-50
*
*
*
Olanzapine
Placebo
*
-60
1
2
3
4
Week of Study
* p < .05. Response curve illustrates four week study of olanzapine (n=54) vs placebo
(n=56) for acute mania (four week study II)
Similar Y-MRS Improvement in
Non-Psychotic and Psychotic
Subjects
Baseline
:0
Study I
three weeks
29.58
27.56
Study II
four weeks
30.8
25.5
-5
Mean
Change -10
(LOCF)
-15
-9.9 *
Psychotic
Non-psychotic
-10.7
-13.0
-15.9 **
-20
*p=0.88; **p=0.41. No difference in mania improvement among olanzapinetreated subjects with and without psychotic features
Y-MRS Total:
Manic vs Mixed Episodes
Study II four weeks
Baseline:
29.19
28.17
0
Manic episode
n=31
-5
Mean
Change
-10
Mixed episode
n=23
-15
-15.39
-13.96
-20
There was no difference in antimanic response (Y-MRS Total beginning to endpoint improvement,
four-week study II) between olanzapine-treated patients in manic or mixed episodes (p=.681)
Symptoms‡
HAMD Improved During Olanzapine
Treatment
Baseline:
0
26.57
25.62
n=21
n=21
Mean
Change -5
in
HAMD21
Total
-6.81
-10
-12.29 *
Olanzapine
Placebo
-15
In patients with depressive symptoms, olanzapine-treated patients had a statistically
significantly greater mean improvement in HAMD21 total scores compared to placebo-treated
patients in this four-week study II acute mania trial.
*p=0.046 ‡HAMD21 total score 20 at baseline
Y-MRS Total:
Lithium Responders vs NonResponders
Study II four weeks
Baseline:
27.67
29.38
0
Most Recent
-3
Lithium Response:
Responder
n=18
-6
Mean
Change
-9
Non-responder
n=24
-12
-15
-18
-14.00
-15.88
There was no difference in antimanic response (Y-MRS Total beginning to endpoint
improvement, four-week study II) between olanzapine-treated patients with history of good
vs poor response to lithium treatment for mania (p=.641)
Baker RW et al. Bipolar Disorders Conference. Phoenix, Arizona, January 2000.
Y-MRS Total: Valproic Acid
Responders
vs Non-Responders
Study II four weeks
Baseline:
30.45
0
29.48
Most Recent
Valproic Acid
Response:
-5
Responder
n=11
Mean
Change -10
Non-responder
n=21
-11.73
-15
-14.67
-20
There was no difference in antimanic response (Y-MRS Total beginning to endpoint
improvement, four-week study II) between olanzapine-treated patients with history of
good vs poor response to valproate treatment for mania (p=.546)
Baker RW et al. Bipolar Disorders Conference. Phoenix, Arizona, January 2000
Treatment-Emergent Adverse
Effects During Acute Mania
Trials
Event
Somnolence
Dry mouth
Dizziness
Asthenia
% Reporting
Olanzapine
(n=125)
Placebo
(n=129)
35%
22%
18%
15%
13%
7%
6%
6%
These four events were the only ones significantly more common (p<0.05) in
olanzapine-treated subjects
GABAPENTIN
•
•
•
•
Anticonvulsant, least effective new drug
Most helpful with anxiety, insomnia, pain
May cause persistent sedation
Excreted by kidneys only, no drug
interaction
• 1200 to 4000 mg/d.
LAMOTRIGINE
• Anticonvulsant, best for Bipolar depression
• Improved cognition, excellent tolerance,
serious autoimmune rash
• Valproate interaction
• 12.5 to 25 mg/wk increments. Dose range of
75 to 300mg/d.
TOPYRAMATE
• May augment other medications?
• Significant cognitive ill effect and
paresthesiae
• BUT SIGNIFICANT WEIGHT LOSS,
AND NEVER UNDERESTIMATE
LOOKING GOOD !!!!!!
• 50 mg qhs, increase by 50 mg/wk. in
divided doses to maximum of 200 mg bid
THYROID AUGMENTATION
• TSH is not reliable indicator of subclinical
hypothyroidism in mood disorder patients
• T3 and T4 in lower range of “normal” cause
cognitive impairment, relapse and lethargy
• Supplemental T4 caused 10/11 Li refractory
to respond
• Large study showed no bone density effect
of high dose T4 treatment
NEVER GIVE UP
It will help patient to be inspired by
us, rather than the other way around